Voyageur Pharmaceuticals (VM) AI Stock Analysis

• Market Cap: C$32.12M
• Dividend Yield: N/A
• Average Volume (3M): 72.03K
• Price to Earnings (P/E): ―
• Beta (1Y): -1.45
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): >-0.01
• Shares Outstanding: 178,438,130
• 10 Day Avg. Volume: 61,621
• 30 Day Avg. Volume: 72,034
• PEG Ratio: -0.33
• Price to Book (P/B): 19.88
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -29.59
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: C$0.17 ▼(-1.76% Downside)

The score is held down primarily by weak financial performance (minimal revenue, large losses, and rising cash burn that implies funding/dilution risk), only partly offset by low leverage and positive equity. Technical indicators are broadly neutral and provide limited support, while valuation is constrained by negative earnings and no dividend yield.

Voyageur Pharmaceuticals Business Overview & Revenue Model

Company Description

Voyageur Pharmaceuticals Ltd. focuses on the development of active pharmaceutical ingredients minerals. The company intends to develop barium and iodine radiocontrast products and bromine based pharmaceutical products. It holds 100% interest in three barium sulfate deposits, including two properties suitable in grade for the pharmaceutical barite marketplace located in British Columbia, Canada; and interests in a high-grade iodine, lithium, and bromine brine project in Utah, the United States. The company was formerly known as Voyageur Minerals Ltd. and changed its name to Voyageur Pharmaceuticals Ltd. in December 2019. Voyageur Pharmaceuticals Ltd. is headquartered in Calgary, Canada.

How the Company Makes Money

Voyageur Pharmaceuticals Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	11.04K	0.00	0.00	0.00	0.00	0.00
Gross Profit	-370.40K	-1.57K	-2.19K	-2.91K	-2.25K	-1.48K
EBITDA	-3.12M	-1.71M	-1.22M	-1.75M	-2.05M	-1.12M
Net Income	-3.13M	-1.71M	-1.40M	-1.75M	-2.05M	-1.14M
Balance Sheet
Total Assets	3.68M	2.60M	2.16M	2.10M	2.57M	1.28M
Cash, Cash Equivalents and Short-Term Investments	943.15K	165.57K	2.08K	31.56K	812.97K	2.97K
Total Debt	40.00K	40.00K	40.00K	25.52K	42.08K	268.41K
Total Liabilities	2.24M	2.15M	727.88K	630.83K	660.64K	968.85K
Stockholders Equity	1.44M	449.96K	1.44M	1.46M	1.91M	306.33K
Cash Flow
Free Cash Flow	-2.44M	-302.29K	-991.25K	-2.00M	-2.09M	-434.13K
Operating Cash Flow	-2.44M	-302.29K	-991.25K	-1.72M	-1.65M	-272.19K
Investing Cash Flow	-213.32K	-165.96K	-174.72K	-274.15K	-432.08K	-151.79K
Financing Cash Flow	3.60M	631.73K	1.14M	1.21M	2.90M	351.34K

Voyageur Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ROMJ	55 Neutral	C$33.59M	10.85	7.78%	―	28.55%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
VM	46 Neutral	C$32.12M	-9.14	-256.01%	―	―	―
AVCN	46 Neutral	C$27.12M	-14.02	-77.67%	―	2.41%	74.61%
LABS	45 Neutral	C$29.45M	-3.63	-19.10%	―	18.06%	34.58%
PCLO	44 Neutral	C$14.62M	-2.65	―	―	15.64%	58.47%
INNO	40 Neutral	C$36.44M	-8.10	-71.80%	―	-3.94%	-17.62%

Voyageur Pharmaceuticals Corporate Events

Voyageur Pharmaceuticals Gains Full Control of Iodine Technology, Names New Director of Chemistry

Voyageur Pharmaceuticals has secured 100% ownership of the proprietary “Mueller Process” iodine extraction technology and appointed its inventor, Dr. Brian Mueller, as Director of Chemistry, strengthening its in-house scientific capabilities and tightening control over key intellectual property. The deal is expected to enhance the company’s iodine extraction projects in the Anadarko Basin by improving cost efficiency, operational flexibility and long-term supply security, while potentially enabling Voyageur’s Streamlined API process to bypass traditional iodine flake production and manufacture iodine drugs directly from brine, positioning the firm to pursue one of the lowest cost structures in the multibillion‑dollar iodine contrast drug market and to tap additional mineral opportunities at its Paradox Basin claims.

The most recent analyst rating on (TSE:VM) stock is a Sell with a C$0.16 price target. To see the full list of analyst forecasts on Voyageur Pharmaceuticals stock, see the TSE:VM Stock Forecast page.

Voyageur Pharmaceuticals Strengthens Board for U.S. Expansion

Voyageur Pharmaceuticals Ltd. has appointed Virginia Alling as an independent director to its board, enhancing its strategic positioning for U.S. market expansion. With over 30 years of experience in corporate banking and capital markets, Alling’s expertise is expected to drive U.S. capital market access and strategic growth, complementing recent board appointments. This move underscores Voyageur’s commitment to assembling a high-caliber board to support commercialization efforts, including FDA approvals and scaling operations, aligning with its vision of sustainable growth and value creation for shareholders.

Voyageur Pharmaceuticals Expands into Mexican Market with Phalanx Partnership

Voyageur Pharmaceuticals has signed a non-exclusive distribution agreement with Phalanx, a leading pharmaceutical distributor in Mexico, to expand its market presence in the Mexican healthcare sector. This partnership is a significant milestone in Voyageur’s international growth strategy, aiming to increase access to its barium-based contrast media products in Latin America, a region with growing demand for high-quality imaging solutions.

Voyageur Pharmaceuticals Expands Board with Wall Street Experts for U.S. Market Growth

Voyageur Pharmaceuticals Ltd. has expanded its board of directors by appointing two seasoned Wall Street executives, Jeffrey J. Kraws and Christopher A. Van Buren, to facilitate its expansion into the U.S. market. This strategic move is expected to attract significant American investment and support Voyageur’s growth in the diagnostic imaging sector. The new directors bring expertise in U.S. capital markets, IPO execution, and regulatory compliance, which will help Voyageur bridge its presence on the TSX Venture Exchange to the U.S. markets. This development aligns with Voyageur’s vision of becoming the first contrast media company with a secure supply chain of domestically produced products, ensuring long-term supply chain security for North American markets. The company is advancing its feasibility studies for the Frances Creek Barium Contrast project and the Oklahoma iodine project, positioning itself as the only vertically integrated radiology drug company globally.